| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Clinical Investigations |
1 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
2 Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California
3 Department of Neurosurgery, David Geffen School of Medicine, UCLA, Los Angeles, California
4 Department of Pathology, David Geffen School of Medicine, UCLA, Los Angeles, California
3'-Deoxy-3'-18F-fluorothymidine (18F-FLT) is a recently developed PET tracer to image tumor cell proliferation. We characterized 18F-FLT PET of brain gliomas and compared 18F-FLT with 18F-FDG PET in side-by-side studies of the same patients. Methods: Twenty-five patients with newly diagnosed or previously treated glioma underwent PET with 18F-FLT and 18F-FDG on consecutive days. Three stable patients in long-term remission were included as negative control subjects. Tracer kinetics in normal brain and tumor were measured. Uptake of 18F-FLT and 18F-FDG was quantified by the standardized uptake value (SUV) and the tumor-to-normal tissue (T/N) ratio. The accuracy of 18F-FLT and 18F-FDG PET in evaluating newly diagnosed and recurrent gliomas was compared. More than half of the patients underwent resection after the PET study and correlations between PET uptake and the Ki-67 proliferation index were examined. Patients were monitored for a mean of 15.4 mo (range, 12–20 mo). The predictive power of PET for tumor progression and survival was analyzed using Kaplan–Meier statistics. Results: 18F-FLT uptake in tumors was rapid, peaking at 5–10 min after injection and remaining stable up to 75 min. Hence, a 30-min scan beginning at 5 min after injection was sufficient for imaging. 18F-FLT visualized all high-grade (grade III or IV) tumors. Grade II tumor did not show appreciable 18F-FLT uptake and neither did the stable lesions. The absolute uptake of 18F-FLT was low (maximum-pixel SUV [SUVmax], 1.33) but image contrast was better than with 18F-FDG (T/N ratio, 3.85 vs. 1.49). 18F-FDG PET studies were negative in 5 patients with recurrent high-grade glioma who subsequently suffered tumor progression within 1–3 mo. 18F-FLT SUVmax correlated more strongly with Ki-67 index (r = 0.84; P < 0.0001) than 18F-FDG SUVmax (r = 0.51; P = 0.07). 18F-FLT uptake also had more significant predictive power with respect to tumor progression and survival (P = 0.0005 and P = 0.001, respectively). Conclusion: Thirty-minute 18F-FLT PET 5 min after injection was more sensitive than 18F-FDG to image recurrent high-grade tumors, correlated better with Ki-67 values, and was a more powerful predictor of tumor progression and survival. Thus, 18F-FLT appears to be a promising tracer as a surrogate marker of proliferation in high-grade gliomas.
Key Words: 18F-FLT • 18F-FDG • Ki-67 • proliferation • brain tumor
This article has been cited by other articles:
|
|
 |
|
  C. H. Wang, J. K. Rockhill, M. Mrugala, D. L. Peacock, A. Lai, K. Jusenius, J. M. Wardlaw, T. Cloughesy, A. M. Spence, R. Rockne, et al. Prognostic Significance of Growth Kinetics in Newly Diagnosed Glioblastomas Revealed by Combining Serial Imaging with a Novel Biomathematical Model Cancer Res., December 1, 2009; 69(23): 9133 - 9140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Ford, J. Herman, E. Yorke, and R. L. Wahl 18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy J. Nucl. Med., October 1, 2009; 50(10): 1655 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Peterson and H. C. Manning Molecular Imaging: 18F-FDG PET and a Whole Lot More J. Nucl. Med. Technol., September 1, 2009; 37(3): 151 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Y. Lee and K. C. P. Li Systems Diagnostics: The Systems Approach to Molecular Imaging Am. J. Roentgenol., August 1, 2009; 193(2): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Menda, L. L. Boles Ponto, K. J. Dornfeld, T. J. Tewson, G. L. Watkins, M. K. Schultz, J. J. Sunderland, M. M. Graham, and J. M. Buatti Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine (18F-FLT) in Head and Neck Cancer Patients Before and Early After Initiation of Chemoradiation Therapy J. Nucl. Med., July 1, 2009; 50(7): 1028 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Vredenburgh, A. Desjardins, D. A. Reardon, and H. S. Friedman Experience with irinotecan for the treatment of malignant glioma Neuro Oncology, February 1, 2009; 11(1): 80 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Veeravagu, Z. Liu, G. Niu, K. Chen, B. Jia, W. Cai, C. Jin, A. R. Hsu, A. J. Connolly, V. Tse, et al. Integrin {alpha}v{beta}3-Targeted Radioimmunotherapy of Glioblastoma Multiforme Clin. Cancer Res., November 15, 2008; 14(22): 7330 - 7339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Manning, N. B. Merchant, A. C. Foutch, J. M. Virostko, S. K. Wyatt, C. Shah, E. T. McKinley, J. Xie, N. J. Mutic, M. K. Washington, et al. Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7413 - 7422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Wei, H. Su, I. J. Hildebrandt, M. E. Phelps, J. Czernin, and W. A. Weber Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma Clin. Cancer Res., June 1, 2008; 14(11): 3416 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ullrich, H. Backes, H. Li, L. Kracht, H. Miletic, K. Kesper, B. Neumaier, W.-D. Heiss, K. Wienhard, and A. H. Jacobs Glioma Proliferation as Assessed by 3'-Fluoro-3'-Deoxy-L-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma Clin. Cancer Res., April 1, 2008; 14(7): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bradbury, D. Hambardzumyan, P. B. Zanzonico, J. Schwartz, S. Cai, E. M. Burnazi, V. Longo, S. M. Larson, and E. C. Holland Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3'-Deoxy-3'-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas J. Nucl. Med., March 1, 2008; 49(3): 422 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Wong and S. Brem Taming Glioblastoma: Targeting Angiogenesis J. Clin. Oncol., October 20, 2007; 25(30): 4705 - 4706. [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al. Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Hammoud, J. M. Hoffman, and M. G. Pomper Molecular Neuroimaging: From Conventional to Emerging Techniques Radiology, October 1, 2007; 245(1): 21 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S.-C. Huang 18F-FDOPA Kinetics in Brain Tumors J. Nucl. Med., October 1, 2007; 48(10): 1651 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G.C. Troost, W. V. Vogel, M. A.W. Merkx, P. J. Slootweg, H. A.M. Marres, W. J.M. Peeters, J. Bussink, A. J. van der Kogel, W. J.G. Oyen, and J. H.A.M. Kaanders 18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients J. Nucl. Med., May 1, 2007; 48(5): 726 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Jacobs, M. A. Rueger, A. Winkeler, H. Li, S. Vollmar, Y. Waerzeggers, B. Rueckriem, C. Kummer, C. Dittmar, M. Klein, et al. Imaging-Guided Gene Therapy of Experimental Gliomas Cancer Res., February 15, 2007; 67(4): 1706 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceyssens, K. Van Laere, T. de Groot, J. Goffin, G. Bormans, and L. Mortelmans [11C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1432 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Leyton, J. P. Alao, M. Da Costa, A. V. Stavropoulou, J. R. Latigo, M. Perumal, R. Pillai, Q. He, P. Atadja, E. W.-F. Lam, et al. In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography. Cancer Res., August 1, 2006; 66(15): 7621 - 7629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber Chaperoning Drug Development with PET J. Nucl. Med., May 1, 2006; 47(5): 735 - 737. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Jacobs, A. Thomas, L. W. Kracht, H. Li, C. Dittmar, G. Garlip, N. Galldiks, J. C. Klein, J. Sobesky, R. Hilker, et al. 18F-Fluoro-L-Thymidine and 11C-Methylmethionine as Markers of Increased Transport and Proliferation in Brain Tumors J. Nucl. Med., December 1, 2005; 46(12): 1948 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Saleem Potential of PET in oncology and radiotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 6 - 16. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
